

CIBMTR Center Number:

CIBMTR Recipient ID:

16. Were tumor metastases present at diagnosis?

- 1 yes
- 2 no
- 3 unknown

Specify metastasis site(s):

17. 1 yes 2 no adrenal gland

18. 1 yes 2 no bone

19. 1 yes 2 no central nervous system (CNS)

20. 1 yes 2 no liver

21. 1 yes 2 no lung

22. 1 yes 2 no hilar or mediastinal nodes

23. 1 yes 2 no retroperitoneum / nodes

24. 1 yes 2 no second kidney

25. 1 yes 2 no other site → 26. Specify site:

27. Was the metastatic disease confirmed by biopsy of metastatic site?

- 1 yes
- 2 no

Initial Renal Carcinoma Management

28. Was surgery performed before any other therapy was undertaken?

- 1 yes
- 2 no

29. Date of surgery:

Month Day Year

Specify the type(s) of surgery:

30. 1 yes 2 no arterial embolization

31. 1 yes 2 no radical nephrectomy → Specify any surgery to surrounding tissues:

35. 1 yes 2 no simple nephrectomy

36. 1 yes 2 no parital nephrectomy

37. 1 yes 2 no resection of metastatic lesions → Specify metastasis site(s):

38. 1 yes 2 no adrenal gland

39. 1 yes 2 no bone

40. 1 yes 2 no central nervous system

41. 1 yes 2 no liver

42. 1 yes 2 no lung

43. 1 yes 2 no hilar or mediastinal nodes

44. 1 yes 2 no retroperitoneum / nodes

45. 1 yes 2 no second kidney

46. 1 yes 2 no other site → 47. Specify:

48. Was the recipient considered to be in complete remission following surgery?

- 1 yes
- 2 no

49. Did the disease metastasize or recur after resection but before any therapy (question 51)?

- 1 yes
- 2 no

50. Date of occurrence / recurrence: date unknown

Month Day Year

CIBMTR Center Number:

CIBMTR Recipient ID:

Renal Carcinoma Status

196. What was the disease status immediately prior to the preparative regimen? (Should match status after last line of therapy.)
(Disease status based on response criteria described below.)

- 1 complete response
- 2 complete response with persistent imaging abnormalities of unknown significance
- 3 partial response
- 4 stable disease
- 5 progressive disease
- 6 not evaluable →
- 7 unknown / not tested

Response Evaluation Criteria in Solid Tumors (RECIST)

- 1 Complete response (CR) – Disappearance of all target lesions for a period of at least one month
- 2 Complete response with persistent imaging abnormalities of unknown significance (CRU)
- 3 Partial response (PR) – At least 30% decrease in the sum of the longest diameter of measured lesions (target lesions) taking as reference the baseline sum of longest diameters
- 4 Stable disease (SD) – Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameters since the treatment started
- 5 Progressive disease (PD) – At least a 20% increase in the sum of the longest diameter of measured lesions (target lesions), taking as reference the smallest sum of the longest diameters recorded since the treatment started or the appearance of one or more new lesions
- 6 Not evaluable (NE), specify reason

198. Signed: _____
Person completing form

Please print name: _____

Phone: (_____) _____

Fax: (_____) _____

E-mail address: _____